Nanotechnology-based strategies against SARS-CoV-2 variants
Source abstract
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630–645 (2020).10.1038/s41565-020-0732-3 ↗
2. Tang, Z. et al. A materials science perspective on tackling COVID-19. Nat. Rev. Mater. 5, 847–860 (2020).10.1038/s41578-020-00247-y ↗
3. Tang, Z. et al. Insights from nanotechnology in COVID-19 treatment. Nano Today 36, 101019 (2021).10.1016/j.nantod.2020.101019 ↗
4. Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475–484 (2021).10.1038/s41577-021-00578-z ↗
5. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).10.1056/NEJMoa2035389 ↗
6. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).10.1056/NEJMoa2034577 ↗
7. Kirtane, A. R. et al. Nanotechnology approaches for global infectious diseases. Nat. Nanotechnol. 16, 369–384 (2021).10.1038/s41565-021-00866-8 ↗
8. Tracking SARS-CoV-2 variants. WHO https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (2022).
9. Krause, P. R. et al. SARS-CoV-2 variants and vaccines. N. Engl. J. Med. 385, 179–186 (2021).10.1056/NEJMsr2105280 ↗
10. Callaway, E. The coronavirus is mutating—does it matter? Nature 585, 174–178 (2020).10.1038/d41586-020-02544-6 ↗
11. Williams, T. C. & Burgers, W. A. SARS-CoV-2 evolution and vaccines: cause for concern? Lancet Respir. Med. 9, 333–335 (2021).10.1016/S2213-2600(21)00075-8 ↗
12. Bian, L. et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev. Vaccines 20, 365–373 (2021).10.1080/14760584.2021.1903879 ↗
13. Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y. & Wallace, A. W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 375, 331–336 (2022).10.1126/science.abm0620 ↗
14. Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393.e2312 (2021).10.1016/j.cell.2021.03.036 ↗
15. Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4236.e4213 (2021).10.1016/j.cell.2021.06.020 ↗
16. Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 600, 523–529 (2021).10.1038/s41586-021-04085-y ↗
17. Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).10.1038/s41467-021-24435-8 ↗
18. COG-UK Mutation Explorer (COG-UK, 2021); https://sars2.cvr.gla.ac.uk/cog-uk/
19. Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917–924 (2021).10.1038/s41591-021-01318-5 ↗
20. Choi, A. et al. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. J. Virol. 95, e01313–01321 (2021).10.1128/JVI.01313-21 ↗
21. Jangra, S. et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2, e283–e284 (2021).10.1016/S2666-5247(21)00068-9 ↗
22. Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939–2954.e2939 (2021).10.1016/j.cell.2021.03.055 ↗
23. Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021).10.1038/s41586-021-03693-y ↗
24. Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 372, 1413–1418 (2021).10.1126/science.abg9175 ↗
25. Levin, E. G. et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).10.1056/NEJMoa2114583 ↗
26. Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N. Engl. J. Med. 385, 1761–1773 (2021).10.1056/NEJMoa2110345 ↗
27. Scott, J., Richterman, A. & Cevik, M. COVID-19 vaccination: evidence of waning immunity is overstated. Brit. Med. J. 374, n2320 (2021).10.1136/bmj.n2320 ↗
28. Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126–2128 (2021).10.1016/S0140-6736(21)02758-6 ↗
29. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).10.1038/s41586-021-04386-2 ↗
30. Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599–601 (2021).10.1056/NEJMc2119641 ↗
31. Takashita, E. et al. Efficacy of antibodies and antiviral drugs against COVID-19 Omicron variant. N. Engl. J. Med. 386, 995–998 (2022).10.1056/NEJMc2119407 ↗
32. Rössler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med. 386, 698–700 (2022).10.1056/NEJMc2119236 ↗
33. Altarawneh, H. N. et al. Protection against the Omicron variant from previous SARS-CoV-2 infection. N. Engl. J. Med. 386, 1288–1290 (2022).10.1056/NEJMc2200133 ↗
34. VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490–495 (2022).10.1038/s41591-021-01678-y ↗
35. Elia, U. et al. Design of SARS-CoV-2 hFc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles. ACS Nano 15, 9627–9637 (2021).10.1021/acsnano.0c10180 ↗
36. Elia, U. et al. Lipid nanoparticle RBD-hFc mRNA vaccine protects hACE2 transgenic mice against a lethal SARS-CoV-2 infection. Nano Lett. 21, 4774–4779 (2021).10.1021/acs.nanolett.1c01284 ↗
37. Kon, E., Elia, U. & Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin. Biotechnol. 73, 329–336 (2022).10.1016/j.copbio.2021.09.016 ↗
38. Baumjohann, D. & Fazilleau, N. Antigen-dependent multistep differentiation of T follicular helper cells and its role in SARS-CoV-2 infection and vaccination. Eur. J. Immunol. 51, 1325–1333 (2021).10.1002/eji.202049148 ↗
39. Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571–1588 (2018). This study demonstrates how modified mRNA-LNP vaccines induce highly potent and durable neutralizing antibody responses.10.1084/jem.20171450 ↗
40. Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity 53, 1281–1295.e1285 (2020).10.1016/j.immuni.2020.11.009 ↗
41. Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e2877 (2021).10.1016/j.immuni.2021.11.001 ↗
42. Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195–197 (2021).10.1038/s41577-021-00526-x ↗
43. Kamar, N. et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. 385, 661–662 (2021).10.1056/NEJMc2108861 ↗
44. Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385, 1244–1246 (2021).10.1056/NEJMc2111462 ↗
45. Falsey, A. R. et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med. 385, 1627–1629 (2021).10.1056/NEJMc2113468 ↗
46. Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 492–494 (2021). This study shows that a third dose does elicit Omicron neutralizing antibodies shortly after administration.10.1056/NEJMc2119358 ↗
47. Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).10.1056/NEJMc2119912 ↗
48. Wu, M. et al. Three-dose vaccination elicits neutralising antibodies against Omicron. Lancet 399, 715–717 (2022).10.1016/S0140-6736(22)00092-7 ↗
49. Tanne, J. H. COVID-19: Moderna plans booster doses to counter variants. Brit. Med. J. 372, n232 (2021).10.1136/bmj.n232 ↗
50. Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. 27, 2025–2031 (2021).10.1038/s41591-021-01527-y ↗
51. Yang, Y. & Du, L. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. Signal Transduct. Target. Ther. 6, 95 (2021).10.1038/s41392-021-00523-5 ↗
52. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).10.1038/s41586-020-2180-5 ↗
53. Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991–998 (2021).10.1126/science.abi4506 ↗
54. Xiao, Y. et al. Emerging mRNA technologies: Delivery strategies and biomedical applications. Chem. Soc. Rev. 51, 3828–3845 (2022).10.1039/D1CS00617G ↗
55. Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1–17 (2022). This report describes circular RNA vaccines for SARS-CoV-2 and its variants.10.1016/j.cell.2022.03.044 ↗
56. Beaudoin, C. A., Bartas, M., Volná, A., Pečinka, P. & Blundell, T. L. Are there hidden genes in DNA/RNA vaccines? Front. Immunol. 13, 801915 (2022).10.3389/fimmu.2022.801915 ↗
57. Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553–559 (2021). This study provides a promising protein nanoparticle platform for developing pancoronavirus vaccines.10.1038/s41586-021-03594-0 ↗
58. Saunders, K. O. et al. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science 366, eaay7199 (2019).10.1126/science.aay7199 ↗
59. Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383–391 (2022).10.1038/s41591-021-01660-8 ↗
60. Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219.e4232 (2021).10.1016/j.cell.2021.06.021 ↗
61. Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432–5447 (2021).10.1016/j.cell.2021.09.015 ↗
62. Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e1317 (2020).10.1016/j.cell.2020.10.043 ↗
63. He, L. et al. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci. Adv. 7, eabf1591 (2021).10.1126/sciadv.abf1591 ↗
64. Zhang, Y.-N. et al. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Sci. Adv. 7, eabj3107 (2021).10.1126/sciadv.abj3107 ↗
65. Aves, K.-L., Goksøyr, L. & Sander, A. F. Advantages and prospects of Tag/Catcher mediated antigen display on capsid-like particle-based vaccines. Viruses 12, 185 (2020).10.3390/v12020185 ↗
66. Janitzek, C. M. et al. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine. Sci. Rep. 9, 5260 (2019).10.1038/s41598-019-41522-5 ↗
67. Brune, K. D. & Howarth, M. New routes and opportunities for modular construction of particulate vaccines: stick, click, and glue. Front. Immunol. 9, 1432 (2018).10.3389/fimmu.2018.01432 ↗
68. Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775–797 (2013).10.1146/annurev-biochem-063011-092449 ↗
69. Vanlandschoot, P. et al. Nanobodies®: new ammunition to battle viruses. Antiviral Res. 92, 389–407 (2011).10.1016/j.antiviral.2011.09.002 ↗
70. Detalle, L. et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 60, 6–13 (2016).10.1128/AAC.01802-15 ↗
71. Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479–1484 (2020).10.1126/science.abe4747 ↗
72. Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473–1479 (2020).10.1126/science.abe3255 ↗
73. Sun, D. et al. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. Nat. Commun. 12, 4676 (2021).10.1038/s41467-021-24963-3 ↗
74. Xu, J. et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature 595, 278–282 (2021).10.1038/s41586-021-03676-z ↗
75. Koenig, P.-A. et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science 371, eabe6230 (2021).10.1126/science.abe6230 ↗
76. Saelens, X. & Schepens, B. Single-domain antibodies make a difference. Science 371, 681–682 (2021).10.1126/science.abg2294 ↗
77. Güttler, T. et al. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J. 40, e107985 (2021).10.15252/embj.2021107985 ↗
78. Ku, Z. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 595, 718–723 (2021).10.1038/s41586-021-03673-2 ↗
79. Tada, T. et al. An ACE2 microbody containing a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2. Cell Rep. 33, 108528 (2020).10.1016/j.celrep.2020.108528 ↗
80. El-Shennawy, L. et al. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat. Commun. 13, 405 (2022).10.1038/s41467-021-27893-2 ↗
81. Zhang, H. et al. Inhalable nanocatchers for SARS-CoV-2 inhibition. Proc. Natl Acad. Sci. USA 118, e2102957118 (2021).10.1073/pnas.2102957118 ↗
82. Wang, C. et al. Membrane nanoparticles derived from ACE2-rich cells block SARS-CoV-2 infection. ACS Nano 15, 6340–6351 (2021).10.1021/acsnano.0c06836 ↗
83. Wang, Z. et al. Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm. Matter 5, 336–362 (2021).10.1016/j.matt.2021.09.022 ↗
84. Xie, F. et al. Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID-19 therapy. Adv. Mater. 33, 2103471 (2021).10.1002/adma.202103471 ↗
85. Li, Z. et al. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. Nat. Nanotechnol. 16, 942–951 (2021). This study describes a nanodecoy that exhibits post-infection therapeutic effects for SARS-CoV-2.10.1038/s41565-021-00923-2 ↗
86. Rao, L. et al. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc. Natl Acad. Sci. USA 117, 27141–27147 (2020).10.1073/pnas.2014352117 ↗
87. Zhang, Q. et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 20, 5570–5574 (2020).10.1021/acs.nanolett.0c02278 ↗
88. Ai, X. et al. Surface glycan modification of cellular nanosponges to promote SARS-CoV-2 inhibition. J. Am. Chem. Soc. 143, 17615–17621 (2021).10.1021/jacs.1c07798 ↗
89. Li, M. et al. Secreted expression of mRNA-encoded truncated ACE2 variants for SARS-CoV-2 via lipid-like nanoassemblies. Adv. Mater. 33, 2101707 (2021).10.1002/adma.202101707 ↗
90. Kim, J., Mukherjee, A., Nelson, D., Jozic, A. & Sahay, G. Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2. Preprint at bioRxiv https://doi.org/10.1101/2020.07.24.205583 (2020).10.1101/2020.07.24.205583 ↗
91. Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8, 1154–1158 (2020).10.1016/S2213-2600(20)30418-5 ↗
92. Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905–913.e907 (2020).10.1016/j.cell.2020.04.004 ↗
93. Haschke, M. et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52, 783–792 (2013).10.1007/s40262-013-0072-7 ↗
94. Romero, C. A., Orias, M. & Weir, M. R. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11, 242–252 (2015).10.1038/nrendo.2015.6 ↗
95. South, A. M. et al. Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data. Clin. Sci. 133, 55–74 (2019).10.1042/CS20171550 ↗
96. Warner, F. J., Rajapaksha, H., Shackel, N. & Herath, C. B. ACE2: from protection of liver disease to propagation of COVID-19. Clin. Sci. 134, 3137–3158 (2020).10.1042/CS20201268 ↗
97. Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 369, 1261–1265 (2020).10.1126/science.abc0870 ↗
98. Glasgow, A. et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 28046–28055 (2020).10.1073/pnas.2016093117 ↗
99. Chan, K. K., Tan, T. J. C., Narayanan, K. K. & Procko, E. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. Sci. Adv. 7, eabf1738 (2021).10.1126/sciadv.abf1738 ↗
100. Higuchi, Y. et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 12, 3802 (2021).10.1038/s41467-021-24013-y ↗